CHICAGO & NATICK, Massachusetts, Nov 11, 2020–Proteintech and HebeCell announce their collaborative partnership to develop proprietary nanobody based chimeric antigen receptor (nCAR) technology for the development and commercialization of iPSC-derived natural killer (iPSC-nCAR-NK) cells, a promising cellular immunotherapy treatment for cancer and other diseases. [Read more…]
– FUJIFILM Cellular Dynamics grants Lonza a non-exclusive right to use their patents related to iPSC generation, including episomal vectors and reprogramming factors, for development and clinical manufacture of iPSC lines for cell therapies
– Lonza grants FUJIFILM Cellular Dynamics expanded use of its non-exclusive license to its innovative Nucleofector™ technology
– The agreement enables drug developers to leverage both companies expertise and technologies for the generation of human-induced pluripotent stem cells through licensing agreements
Despite progress involving the use of induced pluripotent stem cells (iPSCs) within disease modeling and drug discovery applications, it will be a long path to achieve the broad-scale use of iPSC-derived cell types for use in human patients. Within a preclinical context, cell types differentiated from iPSCs are tested for their therapeutic response by using animal models. Then, clinical trials are conducted to assure that essential parameters, such as tumorigenicity, dose toxicity, and immunogenicity, are assessed before authorizing the product for use in human patients. [Read more…]
A number of induced pluripotent stem cell (iPSC) derived disease models have resulted in the discovery of new drugs that have been tested in iPSC-derived cells for efficacy and potential toxicities. Genome editing technologies have also added a new dimension to to the development of personalized medicine using iPSCs. In some cases, iPSC-derived cell types are being explored as novel cell therapeutics. [Read more…]
The Prix Galien MedStartup was awarded on October 26th in Boston to the French cell therapy biotech TreeFrog Therapeutics in the category “Biopharmaceutical Industry”
Organized by the prestigious Galien Foundation and Business France, the Prix Galien MedStartup rewards the best Franco-American collaborations in the pharmaceutical sector.
TreeFrog Therapeutics received this award for the QC-Stem International Consortium, which brings together world-class experts in induced pluripotent stem cell (iPSC) quality from the Harvard Stem Cell Institute and the Dana-Farber Cancer Institute in Boston (USA), the FBRI in Kobe (Japan) and the Imagine Institute in Paris (France).